Drugs / Rezpegaldesleukin
Rezpegaldesleukin
also known as
LY3471851 · Il-2 peg conjugate (nktr-358) · NKTR-358 · REZPEG · Rezpegaldesleukina · Rezpegaldesleukine
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05565729 | Oct 2022 → Feb 2023 | — | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04998487 | Aug 2021 → Jul 2022 | — | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04119557 | Nov 2019 → Jul 2021 | psoriasis | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04133116 | Oct 2019 → Mar 2020 | — | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03556007 | Apr 2018 → Aug 2019 | systemic lupus erythematosus | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04380324 | Mar 2017 → Jan 2019 | — | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07142252 | May 2026 → May 2028 expected | type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT06340360 | Apr 2024 → Nov 2025 overdue | alopecia areata | Nektar Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06136741 | Nov 2023 → May 2025 overdue | atopic eczema | Nektar Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04677179 | Mar 2021 → Aug 2022 | ulcerative colitis | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04433585 | Aug 2020 → Jan 2023 | systemic lupus erythematosus | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07711418 | Aug 2026 → Jun 2028 expected | atopic eczema | Nektar Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT07690371 | Jul 2026 → May 2028 expected | atopic eczema | Nektar Therapeutics | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04081350 Comparator | Dec 2019 → Jun 2022 | atopic eczema | Nektar Therapeutics | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rezpegaldesleukin | “Here we present clinical evidence for the Treg-selective interleukin-2 receptor agonist rezpegaldesleukin (REZPEG) in two randomized, double-blind, placebo-controlled Phase 1b...” PMID 39455575 ↗ Oct 2024 |
| Known as | Il-2 peg conjugate (nktr-358) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095458 ↗ |
| Known as | LY3471851 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565729 ↗ |
| Known as | NKTR-358 | “LY3471851 (NKTR-358) is a potential first-in-class therapeutic that may address an underlying immune system imbalance” NCT04677179 ↗ |
| Known as | REZPEG | “Here we present clinical evidence for the Treg-selective interleukin-2 receptor agonist rezpegaldesleukin (REZPEG) in two randomized, double-blind, placebo-controlled Phase 1b...” PMID 39455575 ↗ Oct 2024 |
| Known as | Rezpegaldesleukina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095458 ↗ |
| Known as | Rezpegaldesleukine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095458 ↗ |
| Action | Activate | “By activating these cells, LY3471851 may act to bring the immune system back into balance.” NCT03556007 ↗ |
| Modality | Protein / enzyme biologic | “pegylated-recombinant-human interleukin-2 (rezpegaldesleukin)” NCT06136741 ↗ |
| Route | Subcutaneous | “multiple subcutaneous (SC) doses of LY3471851” NCT03556007 ↗ |